Meta-analysis of Association between Newer Glucose-Lowering Drugs and Risk of Parkinson's Disease.
Meta-analysis of Association between Newer Glucose-Lowering Drugs and Risk of Parkinson's Disease.
复制标题
新型降血糖药物与帕金森病风险之间关联的荟萃分析。
DOI：
10.1002/mdc3.13893
复制
发表时间：
2023
影响因子：
4
通讯作者：
Guo,Jingchuan
中科院分区：
文献类型：
--
作者：
Tang,Huilin;Lu,Ying;Okun,MichaelS;Donahoo,WilliamT;Ramirez-Zamora,Adolfo;Wang,Fei;Huang,Yu;Chen,Wei-Han;Virnig,BethA;Bian,Jiang;Guo,Jingchuan
目的通过对随机结果试验的荟萃分析，研究新型降糖药物对帕金森病发病风险的影响。方法采用随机安慰剂对照结果试验，在有或无2型糖尿病的受试者中，报道与三种新型降糖药物(即二肽基肽酶-4抑制剂、高血糖素样肽-1受体激动剂和钠-葡萄糖共转运蛋白-2抑制剂)相关的PD事件。用Peto‘s方法估计合并优势比(OR)和95%可信区间(CI)。结果本研究纳入24项试验，涉及185,305名受试者中的33例帕金森病患者，平均随访时间为2.2 年。与安慰剂相比，较新的GLD与较低的PD风险显著相关(OR：0.50；95%CI：0.25-0.98)。结论较新的GLD可能与PD风险降低相关；然而，需要更大的数据集来证实或驳斥这一观点。
BackgroundThe association between newer classes of glucose‐lowering drugs (GLDs) and the risk of Parkinson's disease (PD) remains unclear.ObjectiveThe aim was to examine the effect of newer GLDs on the risk of PD through a meta‐analysis of randomized outcome trials.MethodsThe methods included randomized placebo‐controlled outcome trials that reported PD events associated with three newer classes of GLDs (ie, dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists, and sodium‐glucose co‐transporter‐2 inhibitors) in participants with or without type 2 diabetes. The pooled odds ratio (OR) and 95% confidence interval (CI) were estimated using Peto's method.ResultsThe study included 24 trials involving 33 PD cases among 185,305 participants during a median follow‐up of 2.2 years. Newer GLDs were significantly associated with a lower PD risk (OR: 0.50; 95% CI: 0.25–0.98) than placebo.ConclusionNewer GLDs may possibly be associated with a decreased risk of PD; however, larger datasets are required to confirm or refute this notion.